NCT06952881Recruiting
A Study on COPD Phenotypes, Endotypes and Treatable Traits
Source: ClinicalTrials.gov · Last updated 22 Oct 2026
Brief summary (registry, in English)
Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous and multisystemic disease with progressive increasing morbidity and mortality. COPD is now widely accepted as a heterogeneous condition with multiple phenotypes and endotypes.The recognition of COPD phenotypes and endotypes has significantly impacted the management of the disease. Furthermore, treatable traits (TTs) are recognizable phenotypic or endotypic characteristics that can be assessed and successfully targeted by therapy to improve a clinical outcome in a patient with airway disease. The healthcare system in Hong Kong is different from that of other places. Previous studies in Hong Kong only looked at specific endotypes; an example is the eosinophils cut-off to predict COPD exacerbations and the treatment effect of applying interventions to certain phenotypes, e.g. approaching the exacerbation phenotype with a comprehensive care programme. There is not much information on the overall phenotypes, endotypes, and TTs of COPD patients in Hong Kong. The characteristics of the patients would help to further assess whether the multi-TT approach can improve their outcomes. This study aims to assess 1. the phenotypes, endotypes and treatable traits of COPD patients over time 2. Outcome of patients according to their phenotypes, endotypes and treatable traits over a period of 3 years. 4\) Clustering analyses will also be employed to assess groups of patients with similar characteristics and to assess the change in their outcome over time.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 460 (estimated)
- First submitted
- 20 Apr 2025
- Start date
- 2 May 2025
- Primary completion date
- 24 Apr 2029
- Lead sponsor
- Chinese University of Hong Kong
- Diseases
- COPD
- NCT number
- NCT06952881
What you commit to
- Study type: Observational
- Planned participants: 460
- From 2 May 2025 to the primary completion date, 24 Apr 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Serious disease that would hinder the patient from having follow-up for 3 years, e.g. late-stage malignancy, severe heart failure and severe renal failure not on dialysis.
Other
- Unable to provide written informed consent.
Who the study is looking for
- 1\) Patient with COPD with compatible history and lung function assessment according to Global Obstructive Lung Disease (GOLD): Patient has chronic respiratory symptoms (dyspnoea, cough, sputum production and exacerbations due to abnormalities of the airway (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive, airflow limitation. Lung function assessment with forced spirometry demonstrated the presence of a post-bronchodilator FEV1/FVC \<70%.14 2) Patient with age ≥40 years
Age in the registry: 40 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Chinese University of Hong Kong Coordinator of this site? Confirm its status | Hong Kong | Hong Kong | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.